1. Baumann MH, Majumdar S, Le Rouzic V, Hunkele A, Uprety R, Huang XP, Xu J, Roth BL, Pan Y-X, Pasternak GW (2017) Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology.
https://doi.org/10.1016/j.neuropharm.2017.08.016
2. EMCDDA (2014) EMCDDA–Europol Joint Report on a new psychoactive substance: 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (‘MT-45’).
http://www.emcdda.europa.eu/system/files/publications/810/TDAS14007ENN_477731.pdf_en
. Accessed 25 Aug 2017
3. European Patent Office (1976) 1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and their salts and the preparation thereof. US Patent 3,957,788. Issued 18th May 1976.
https://worldwide.espacenet.com/publicationDetails/biblio?CC=US&NR=3957788&KC=&FT=E&locale=en_EP
. Accessed 21 Aug 2017
4. Nakamura H, Shimizu M (1976) Comparative study of 1-(cyclohexyl-4-(1,2-diphenylethyl)- piperazine (MT-45) and its enantiomorphs on analgesic and other pharmacological activities in experimental animals. Arch Int Pharmacodyn Ther 221:105–121
5. Prekupec M, Mansky P, Baumann M (2017) Misuse of novel synthetic opioids: a deadly new trend. J Addict Med 11:256–265